全文获取类型
| 收费全文 | 170371篇 |
| 免费 | 6727篇 |
| 国内免费 | 315篇 |
专业分类
| 耳鼻咽喉 | 3035篇 |
| 儿科学 | 6373篇 |
| 妇产科学 | 4356篇 |
| 基础医学 | 23979篇 |
| 口腔科学 | 4806篇 |
| 临床医学 | 12702篇 |
| 内科学 | 31024篇 |
| 皮肤病学 | 4672篇 |
| 神经病学 | 15695篇 |
| 特种医学 | 8777篇 |
| 外国民族医学 | 24篇 |
| 外科学 | 28279篇 |
| 综合类 | 1111篇 |
| 一般理论 | 37篇 |
| 预防医学 | 7996篇 |
| 眼科学 | 4588篇 |
| 药学 | 11816篇 |
| 中国医学 | 350篇 |
| 肿瘤学 | 7793篇 |
出版年
| 2023年 | 760篇 |
| 2021年 | 1269篇 |
| 2020年 | 1122篇 |
| 2019年 | 1308篇 |
| 2018年 | 2864篇 |
| 2017年 | 2356篇 |
| 2016年 | 3284篇 |
| 2015年 | 3656篇 |
| 2014年 | 3824篇 |
| 2013年 | 5385篇 |
| 2012年 | 8333篇 |
| 2011年 | 7750篇 |
| 2010年 | 4583篇 |
| 2009年 | 3677篇 |
| 2008年 | 7682篇 |
| 2007年 | 8539篇 |
| 2006年 | 8568篇 |
| 2005年 | 8983篇 |
| 2004年 | 8537篇 |
| 2003年 | 8440篇 |
| 2002年 | 8327篇 |
| 2001年 | 6178篇 |
| 2000年 | 6244篇 |
| 1999年 | 5393篇 |
| 1998年 | 1569篇 |
| 1997年 | 1300篇 |
| 1996年 | 986篇 |
| 1995年 | 796篇 |
| 1994年 | 744篇 |
| 1992年 | 2384篇 |
| 1991年 | 2315篇 |
| 1990年 | 2274篇 |
| 1989年 | 2120篇 |
| 1988年 | 1854篇 |
| 1987年 | 1842篇 |
| 1986年 | 1703篇 |
| 1985年 | 1640篇 |
| 1984年 | 1282篇 |
| 1983年 | 1021篇 |
| 1979年 | 1376篇 |
| 1978年 | 1007篇 |
| 1977年 | 849篇 |
| 1975年 | 1078篇 |
| 1974年 | 1113篇 |
| 1973年 | 1014篇 |
| 1972年 | 1023篇 |
| 1971年 | 994篇 |
| 1970年 | 883篇 |
| 1969年 | 825篇 |
| 1968年 | 797篇 |
排序方式： 共有10000条查询结果，搜索用时 31 毫秒
11.
12.
13.
14.
Rafiye Ciftciler Haluk Demiroglu Yahya Buyukasık Elifcan Aladag Salih Aksu Ibrahim C. Haznedaroglu Nilgun Sayınalp Osman Ozcebe Umit Yavuz Malkan Hakan Goker 《Clinical Lymphoma, Myeloma & Leukemia》2019,19(3):177-182
Background
Refractory acute myeloid leukemia (AML) includes AML includes failure of disease to respond to standard induction chemotherapy, relapse within 6 months after first CR, and 2 or more relapses. The outcome of these patients is usually very poor; only a small proportion can be rescued by allogenic hematopoietic stem-cell transplantation (allo-HSCT). The aim of this study was to evaluate the efficacy and feasibility of allo-HSCT in patients with refractory AML.Patients and Methods
We retrospectively analyzed the clinical outcome of 91 patients who were diagnosed with treatment-refractory AML at Hacettepe University Hospital between January 2002 and June 2018. Patients' disease status included refractory AML, defined as failure to respond to standard induction chemotherapy and relapse within 6 months after first complete remission.Results
The median follow-up was 12 months (range, 0.5-184 months) for the entire group. Kaplan-Meier estimates of the 3-year overall survival for patients who underwent allo-HSCT and patients who received only salvage chemotherapy were 67% and 12%, respectively. Additionally, the Kaplan-Meier estimates of 5-year overall survival for patients who underwent allo-HSCT and patients who received only salvage chemotherapy were 44% and 4%, respectively (P < .001). Complete remission was obtained in 25 patients (83.3%) who underwent allo-HSCT; however, the disease of only 3 patients (3.8%) exhibited complete response after salvage chemotherapy.Conclusion
Allo-HSCT is still the best-known treatment option with curative potential in patients with treatment-refractory AML. Therefore, all efforts should be made in an attempt to find a suitable matched donor in order to perform allo-HSCT. 相似文献15.
16.
17.
18.
19.
20.
Stephan Koter Tina U. Cohnert Korbinian B. Hindermayr Jörg Lindenmann Maximilian Brückner Wolfgang K. Oswald Georg Werkgartner Doris Wagner 《Journal of vascular surgery》2019,69(4):1227-1232